Immunocore (NASDAQ:IMCR) Hits New 1-Year Low - Should You Sell?

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Friday . The company traded as low as $27.19 and last traded at $27.54, with a volume of 127269 shares traded. The stock had previously closed at $29.04.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Mizuho reduced their price target on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research report on Monday. HC Wainwright reissued a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, March 12th. Needham & Company LLC reaffirmed a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a research report on Wednesday, March 12th. Finally, Morgan Stanley restated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a research note on Friday, March 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $65.18.

Immunocore Stock Up 6.5 %

The business has a 50 day moving average price of $29.12 and a 200 day moving average price of $30.55. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The stock has a market cap of $1.31 billion, a PE ratio of -27.49 and a beta of 0.75.

Remove Ads

Insider Transactions at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the company's stock in a transaction dated Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the transaction, the director now directly owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 9.10% of the company's stock.

Hedge Funds Weigh In On Immunocore

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its position in shares of Immunocore by 3,318.1% in the first quarter. GAMMA Investing LLC now owns 19,107 shares of the company's stock valued at $5,670,000 after buying an additional 18,548 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in Immunocore during the fourth quarter worth $4,868,000. GF Fund Management CO. LTD. acquired a new stake in shares of Immunocore in the fourth quarter valued at about $25,000. Woodline Partners LP raised its position in shares of Immunocore by 19.4% during the 4th quarter. Woodline Partners LP now owns 328,059 shares of the company's stock worth $9,678,000 after purchasing an additional 53,378 shares during the last quarter. Finally, Tang Capital Management LLC lifted its stake in Immunocore by 40.7% in the 4th quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after buying an additional 450,000 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.